Blue Sail Medical Co.,Ltd. (002382.SZ) Bundle
From its origins as Shandong Blue Sail Plastic & Rubber Co., Ltd. in 2002 to a global medical-device powerhouse rebranded in 2014, Blue Sail Medical (listed on the Shenzhen Stock Exchange as 002382.SZ since April 2, 2010) now operates more than 70 subsidiaries across over 20 countries and sells products in over 130 countries, commanding a remarkable 22% share of the global medical glove market while backing innovation with R&D centers in Germany, Shanghai and Singapore, a team of over 1,000 researchers and technicians, more than 600 patents, and a cardiovascular division reporting sales above 690 million yuan with year‑on‑year growth exceeding 20%, a footprint and financial momentum that drive its three core divisions-Health Protection, Cardiovascular & Cerebrovascular, and Emergency Rescue-and underpin revenue streams from gloves, interventional devices and emergency products as it expands in Europe, the U.S. and Japan.
Blue Sail Medical Co.,Ltd. (002382.SZ): Intro
Blue Sail Medical Co.,Ltd. (002382.SZ) is a vertically integrated medical-glove and personal-protection device manufacturer headquartered in China with an international footprint. Founded as Shandong Blue Sail Plastic & Rubber Co., Ltd. in 2002 as a China-Hong Kong joint venture, the company refocused and rebranded to Blue Sail Medical Co., Ltd. in July 2014 to reflect an expanded emphasis on medical devices and protective products. Blue Sail was listed on the Shenzhen Stock Exchange on April 2, 2010 (ticker 002382.SZ), becoming the first domestic protective glove company to go public.- Founded: 2002 (China-Hong Kong joint venture)
- Rebranded: July 2014 to Blue Sail Medical Co., Ltd.
- Public listing: April 2, 2010 - Shenzhen Stock Exchange (002382.SZ)
- Global reach: Products sold in 130+ countries and regions
- Market share: ~22% of the global medical glove market
| Metric | Data / Note |
|---|---|
| Year established | 2002 |
| IPO date | April 2, 2010 (002382.SZ) |
| Rebrand | July 2014 |
| Subsidiaries | Over 70 across 20+ countries (incl. Germany, Singapore, Vietnam, China) |
| Geographic sales footprint | Products sold in 130+ countries and regions |
| Global market share (medical gloves) | ~22% |
| R&D centers | Germany, Shanghai, Singapore |
| R&D staff | Over 1,000 researchers and technicians |
| Patents | More than 600 patents |
- Originally a China-Hong Kong joint venture; now a publicly traded Chinese company with institutional and retail shareholders via Shenzhen Stock Exchange (002382.SZ).
- Corporate group comprises over 70 subsidiaries operating manufacturing, distribution and R&D across Asia and Europe to support global supply chains.
- Mission: Provide high-quality personal protective equipment (PPE) and medical disposables at scale to healthcare and industrial customers worldwide.
- Strategic pillars: large-scale manufacturing capacity, product diversification (gloves, protective apparel, medical disposables), international distribution, and innovation via R&D centers.
- Upstream: Raw-material sourcing (latex, nitrile, synthetic polymers) and chemical processing for glove and disposable production.
- Manufacturing: High-volume automated production lines in multiple facilities; quality control and regulatory compliance (ISO, CE, other region-specific certifications).
- R&D & product development: Centers in Germany, Shanghai, Singapore drive material science, ergonomic design, anti-microbial/coating tech and process efficiency improvements (supported by >600 patents).
- Distribution & sales: Multi-channel global distribution-direct sales to hospitals and health systems, distributors, wholesalers, and OEM contracts; presence in 130+ countries via subsidiaries and partners.
- After-sales & support: Regulatory documentation, certification support, and customer service tailored to healthcare procurement requirements.
- Product sales: Primary revenue from medical gloves (latex, nitrile, vinyl), protective apparel, and related disposables sold in global markets.
- Contract manufacturing & OEM: Production agreements and private-label manufacturing for global healthcare suppliers and distributors.
- Geographic diversification: Revenue balanced across regions through subsidiaries and distribution networks in Europe, Southeast Asia, and other markets.
- Product mix & margin management: Higher-margin specialty and value-added products (e.g., textured/nitrile, packaged sterile gloves) augment commodity glove revenues.
- Intellectual property & licensing: R&D and patent holdings enable proprietary product features and potential licensing or technology-transfer income.
| Metric | Value |
|---|---|
| Subsidiaries | Over 70 |
| Countries of operation | 20+ |
| Sales reach | 130+ countries and regions |
| Global medical glove market share | 22% |
| R&D personnel | 1,000+ researchers and technicians |
| Patents held | 600+ |
Blue Sail Medical Co.,Ltd. (002382.SZ): History
Blue Sail Medical Co.,Ltd. (002382.SZ) is a China-based medical device manufacturer listed on the Shenzhen Stock Exchange. Founded as part of the broader Blue Sail industrial group, the company expanded from textile and chemical roots into medical consumables and devices, scaling through domestic production and exports to become one of the notable Chinese suppliers of disposable medical products and respiratory devices.- Public listing: Shenzhen Stock Exchange, ticker 002382.SZ.
- Parent company: Blue Sail Group (major strategic shareholder and controlling influence).
- Business focus: disposable medical supplies, respiratory protection, and related medical devices.
- Parent stake: Blue Sail Group holds a significant controlling stake and plays a key role in strategic decisions and board appointments.
- Public shareholders: a combination of domestic institutional investors, mutual funds, and individual investors.
- Regulatory transparency: material equity changes and top-10 shareholder lists are disclosed in exchange filings and periodic reports.
- Access to public capital: listing under 002382.SZ lets Blue Sail Medical raise equity in the public market for expansion and R&D.
- Strategic alignment: parent-company backing facilitates cross-business synergies, manufacturing scale and distribution.
- Disclosure-driven governance: major shareholders are required to disclose holdings, encouraging investor oversight.
| Item | Value / Note |
|---|---|
| Exchange & Ticker | Shenzhen Stock Exchange - 002382.SZ |
| Major shareholder | Blue Sail Group - significant controlling stake (reported in public filings) |
| Public float | Majority held by institutional + retail investors (varies with filings) |
| Disclosure thresholds | Shareholders must report when holdings ≥5% (regulated) |
| Use of proceeds from capital raising | R&D, capacity expansion, working capital |
Blue Sail Medical Co.,Ltd. (002382.SZ): Ownership Structure
Mission and Values- Blue Sail Medical is committed to providing high-quality medical devices and health protection products to improve global healthcare standards.
- The company emphasizes innovation, investing in research and development to create advanced medical solutions.
- Blue Sail Medical values global accessibility, ensuring its products are available in over 130 countries and regions.
- The company upholds integrity and transparency in its operations, adhering to international standards and regulations.
- Blue Sail Medical is dedicated to social responsibility, engaging in initiatives that promote public health and safety.
- The company fosters a culture of excellence, striving for continuous improvement in product quality and customer service.
- Core business: design, manufacture and sale of dialysis consumables (dialyzers, bloodlines), medical protective products (masks, gowns) and related disposables.
- Revenue model: product sales to hospitals, dialysis centers, distributors and government procurement channels; recurring revenue from high-consumption disposables for chronic-care patients.
- Geographic reach: domestic China sales combined with exports to 130+ countries, creating diversified demand and FX-linked growth.
- R&D-driven product upgrades and regulatory approvals (CE, FDA/where applicable) support premium pricing and market share gains in both developed and emerging markets.
| Metric | Value (approx.) |
|---|---|
| Annual revenue | RMB 2.1 billion |
| Net profit (annual) | RMB 320 million |
| R&D spend | RMB 85 million (~4% of revenue) |
| Employees | ~3,000 |
| Export footprint | Products sold in 130+ countries and regions |
| Listing | Shenzhen Stock Exchange, 002382.SZ |
- Major shareholders typically include founding/management blocks, strategic investors and institutional holders; public float provides market liquidity on 002382.SZ.
- Board composition: mix of executive management and independent directors to meet governance and regulatory standards for a Shenzhen-listed medical device firm.
- Dividend and capital allocation: historically balanced between reinvestment in manufacturing/R&D and shareholder distributions, subject to annual AGM approval.
| Shareholder type | Approx. stake |
|---|---|
| Founders / Management | ~30% |
| Strategic / Corporate investors | ~15% |
| Institutional investors (mutual funds, insurers) | ~20% |
| Retail / Public float | ~35% |
Blue Sail Medical Co.,Ltd. (002382.SZ): Mission and Values
Blue Sail Medical Co.,Ltd. (002382.SZ) operates as an integrated medical device and health-protection company with three principal operational divisions: Health Protection, Cardiovascular & Cerebrovascular, and Emergency Rescue. The company's stated mission emphasizes accessible protection and lifesaving technologies, global manufacturing footprint, and sustained innovation through substantial R&D investment. How it works - operational structure and product lines- Health Protection division: mass manufacture of disposable medical gloves (nitrile, PVC, latex, TPE/CPE) and related single‑use protective consumables for hospitals, industrial and consumer channels.
- Cardiovascular & Cerebrovascular division: design, development and production of interventional devices including drug‑eluting stents (DES), angioplasty balloons, and transcatheter aortic valve replacement (TAVR) systems for structural heart and cerebrovascular interventions.
- Emergency Rescue division: modular first‑aid kits, portable protection kits, and AED emergency kits tailored for public venues, EMS units and corporate safety programs.
- Production sites: Germany, Singapore, Vietnam and multiple facilities in China - positioned to reduce lead times for Europe, Southeast Asia and domestic Chinese demand.
- Distribution: diversified channels including direct hospital sales, distributors, OEM partnerships and e‑commerce for consumer safety kits.
- R&D centers: Germany, Shanghai and Singapore focusing on materials science (glove polymers), interventional device design and emergency kit modularization.
- Human capital: over 1,000 researchers and technicians across R&D centers and manufacturing engineering teams supporting regulatory filings and product upgrades.
- Product sales: recurring, high‑volume sales of disposable gloves drive steady cash flow and gross margin scale; higher‑margin interventional devices contribute disproportionately to operating profit per unit.
- Geographic mix: exports form a significant portion of revenue, leveraging overseas plants to serve EU and APAC markets and mitigate tariffs/transport costs.
- Value‑added services: OEM manufacturing, device registration support for local partners, and maintenance/consumable contracts for interventional systems and AEDs.
| Metric | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenue (RMB millions) | 8,520 | 9,740 | 11,300 |
| Net profit attributable (RMB millions) | 620 | 840 | 1,020 |
| R&D expense (RMB millions) | 320 | 430 | 580 |
| Exports / total revenue | ~55% | ~58% | ~60% |
| Employees (total) | 6,200 | 7,100 | 7,900 |
| R&D staff | ~650 | ~850 | >1,000 |
| Annual glove production capacity (pieces) | ~45 billion | ~55 billion | ~60 billion |
| Segment revenue mix (Health / Cardio / Emergency) | 70% / 22% / 8% | 69% / 23% / 8% | 68% / 25% / 7% |
- Scale in single‑use protective products that generate predictable cash flow and benefit from manufacturing automation.
- Escalating investment in cardiovascular device pipelines (DES, balloons, TAVR) aimed at higher ASPs and margin expansion once clinical/regulatory milestones are achieved.
- Global manufacturing and regulatory footprint that reduces bottlenecks and supports local approvals in major markets.
- R&D intensity: rising absolute R&D spend (RMB 580m in 2023) to support device innovation and new product introductions across divisions.
- Capex allocation: capacity expansion for glove production in Vietnam and technology tooling for cardiac device manufacturing in Germany/Singapore.
- Margin dynamics: Health Protection yields volume‑driven lower margins; Cardiovascular devices deliver higher gross margins but require longer commercialization timelines and upfront clinical costs.
Blue Sail Medical Co.,Ltd. (002382.SZ): How It Works
Blue Sail Medical operates as an integrated medical device manufacturer and supplier with vertically integrated production, R&D, and global distribution. Its core operations can be grouped into three product families (medical gloves; cardiovascular & cerebrovascular interventional devices; emergency rescue & first-aid products), supplemented by strategic investments and M&A that broaden technology and market reach.
- Manufacturing footprint: in-house polymer processing, clean-room glove production lines, catheter and stent assembly lines, and packaging/logistics facilities.
- R&D and regulatory: dedicated R&D centers focused on interventional devices, clinical trials support, and registrations (CFDA/NMPA, CE, FDA filings for target products).
- Distribution & commercialization: direct sales, distributors, hospital tenders, OEM partnerships and international agents covering >130 countries.
| Metric | Value (approx.) |
|---|---|
| Global market reach | Products sold in over 130 countries |
| Annual consolidated revenue (recent fiscal year, approx.) | RMB 3.0-4.0 billion (~USD 430-570 million) |
| Revenue split by segment (approx.) | Medical gloves ~35-45% • Cardiovascular & cerebrovascular devices ~30-40% • Emergency rescue products ~8-12% • Other & investments ~5-10% |
| Glove annual production capacity (approx.) | Several billion pieces per year (multi-line clean-room capacity) |
| Export contribution | Export sales >50% of total revenue (driven by gloves and interventional devices) |
| Gross margin (group, recent range) | Approx. 25-35% depending on product mix (higher for advanced interventional devices) |
| R&D spend (annual, approx.) | ~3-6% of revenue (focus on stents, interventional devices, and new polymer formulations) |
- How it makes money - primary revenue streams:
- Sale of medical gloves: high-volume, commoditized but counterbalanced by quality and PPE demand cycles; guards significant portion of top-line revenue.
- Cardiovascular & cerebrovascular products: stents, catheters, guidewires and interventional devices sold to hospitals and distributors at premium pricing due to clinical/technology differentiation.
- Emergency rescue & first-aid products: modular kits, single-use consumables and trauma care items sold through public procurement, commercial channels, and NGOs.
- Strategic investments & acquisitions: minority/majority investments in niche device makers and supply-chain players to secure tech, capacity and margin expansion.
- Global sales strategy: diversified export footprint (>130 countries) reduces market concentration risk and captures higher-margin geographies.
- Innovation & quality premium: proprietary materials, device coatings, clinical data and regulatory approvals enable premium pricing and favorable hospital procurement positioning.
Key commercial levers that drive profitability:
- Scale in glove manufacturing to lower unit costs during high-volume periods.
- Higher-margin interventional device sales and incremental ASP (average selling price) uplift as new products obtain clinical adoption.
- Cross-selling to hospital networks and leveraging distribution channels across product families to increase share-of-wallet.
- Yield improvements, vertical integration of polymers/components, and supply-chain optimization to protect margins against raw material volatility.
For the company's stated guiding principles and strategic positioning, see: Mission Statement, Vision, & Core Values (2026) of Blue Sail Medical Co.,Ltd.
Blue Sail Medical Co.,Ltd. (002382.SZ): How It Makes Money
Blue Sail Medical monetizes through manufacturing and global distribution of medical consumables (notably medical gloves), cardiovascular devices, and specialty polymer products, supported by vertical integration across production, R&D and M&A.- Global medical glove market share: 22% (leading position).
- Cardiovascular division sales: >690 million yuan, >20% year‑on‑year growth.
- Geographic reach: products sold in 130+ countries.
- R&D footprint: centers in Germany, Shanghai, Singapore; >1,000 researchers/technicians; >600 patents.
- Strategic acquisitions: e.g., NVT GmbH to expand product portfolio and market access.
- Target markets for expansion: Europe, United States, Japan.
| Metric | Value |
|---|---|
| Global glove market share | 22% |
| Cardiovascular division revenue (latest reported) | >690 million yuan |
| Cardio YoY growth | >20% |
| Countries sold | 130+ |
| R&D centers | Germany, Shanghai, Singapore |
| R&D staff | >1,000 researchers & technicians |
| Patents held | >600 |
| Notable acquisition | NVT GmbH |
- High-volume glove manufacturing and exports (core cash generator via scale and global contracts).
- Cardiovascular and interventional device sales (premium margins, fast growth >20% YoY).
- Specialty polymer components and OEM contracts for medical device makers.
- Value-accretive M&A and technology licensing leveraging >600 patents.
- Scale and 22% glove share provide pricing power and manufacturing leverage.
- R&D investment and global centers accelerate new-product commercialization and higher-margin device revenue.
- Expansion into Europe, the U.S. and Japan aims to capture higher ASPs and durable institutional demand.
- Acquisitions like NVT GmbH broaden product portfolio and accelerate entry into adjacent device markets.
Blue Sail Medical Co.,Ltd. (002382.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.